MUMBAI - Pfizer has turned its attention to establishing a bigger presence in the U.S. for marketing generic drugs, terming it as an "engine of positive growth." The world's largest drug maker has signed a series of licensing agreements with India's Aurobindo Pharma to acquire rights of 39 generic solid oral dose products and 12 sterile injectable products
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
